SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): May 17, 2010
SHENGTAI
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
(State
or other jurisdiction of incorporation)
|
000-51312
(Commission
File
Number)
|
54-2155579
(IRS
Employer
Identification
No.)
|
|
Changda
Road East
Development
District, Changle County
Shandong,
PRC
(Address
of principal executive offices)
|
262400
(Zip
Code)
|
Registrant’s
telephone number, including area code:
011-86-536-6295802
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written communications pursuant
to Rule 425 under the Securities Act (17
CFR.425)
|
|
o
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 DFR
240.14a-12)
|
|
o
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement communications
pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item
2.02
|
Results
of Operations and Financial
Condition.
|
On May
17, 2010, Shengtai Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), announced its results of operations for the third quarter ended
March 31, 2010. A copy of the related press release is attached
hereto as Exhibit 99.1.
The
information in this Current Report, including Exhibit 99.1, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “
Exchange
Act
”), or incorporated subject to the liabilities of that section or
Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “
Securities Act
”), and
shall not be incorporated by reference in any registration statement or other
document filed under the Securities Act or the Exchange Act, whether made before
or after the date hereof, regardless of any general incorporation language in
such filings, except as shall be expressly set forth by specific reference in
such a filing.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits.
99.1
Press release dated May 17, 2010,
issued by Shengtai Pharmaceuticals, Inc.
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
SHENGTAI
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
Dated:
May 17, 2010
|
|
|
|
By:
/s/ Qingtai
Liu
|
|
|
Name:
Qingtai Liu
|
|
|
Title:
Chief Executive Officer
|